Log in
RegisterMR: Different shapes [Dissolution / BCS / IVIVC]
posted by Helmut 
– Vienna, Austria, 2021-08-05 15:43 (1267 d 20:52 ago) – Posting: # 22512
Views: 3,265
Hi Farmacevt,
The latter. The EMA is concerned about the surface area/volume ratio potentially influencing PK. See this presentation of Henrike Potthast (EUFEPS workshop, Bonn, June 2013).
Sorry, no idea…
❝ 1. Does the term shape is referring to the shape of the dissolution curve or to the shape of the dosage form (shape of the tbl.)?
The latter. The EMA is concerned about the surface area/volume ratio potentially influencing PK. See this presentation of Henrike Potthast (EUFEPS workshop, Bonn, June 2013).
❝ 2. if there is deviation from quantitatively proportional composition and requirements for biowaiver set in the Guideline CPMP/EWP/QWP/1401/98 are fulfilled. Is it sufficient to demonstrate similarity based on f2 factor only or still the shape of the tablets should be the same in order to use biowaiver approach and waive BE study?
Sorry, no idea…
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна!![[image]](https://static.bebac.at/pics/Blue_and_yellow_ribbon_UA.png)
Helmut Schütz
![[image]](https://static.bebac.at/img/CC by.png)
The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Dif-tor heh smusma 🖖🏼 Довге життя Україна!
Helmut Schütz
The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Complete thread:
- Prolonged release drug Farmacevt 2021-07-30 17:31 [Dissolution / BCS / IVIVC]
![[Mix]](https://static.bebac.at/img/mix.png "open in Mix view")
- MR: Different shapesHelmut 2021-08-05 13:43
Ing. Helmut Schütz